Effect of comprehensive intervention on androgen level in patients with polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2020.04.004

Abstract

Abstract: Objective To evaluate the changes of androgen level in patients with polycystic ovary syndrome (PCOS) after comprehensive intervention. Methods A total of 88 women (PCOS group) who were willing to receive comprehensive intervention were selected as the study group from the patients with PCOS in Beijing Obstetrics and Gynecology Hospital, Capital Medical University, from March 2019 to February 2020. Totally 44 healthy women were included as the control group in the same period according to the proportion of 2:1. The observation indexes were compared with each other before and after treatment in PCOS group and between PCOS group and control group after treatment. Observation indexes include:body mass index (BMI),aist circumference、follicle stimulating hormone(FSH),luteinizing hormone(LH),LH/FSH,total testosterone(TT),free testosterone(FT),sex hormone binding globulin(SHBG),anti-Müllerian hormone(AMH). Results Before treatment, there was no significant difference in age and height between the two groups (P>0.05). The weight, BMI, waist circumference, AMH, LH, LH/FSH, and TT were significantly higher whereas FSH and SHBG were significantly lower than those of the control group (P<0.05). In PCOS group, before and after comprehensive intervention treatment, weight, BMI, waist circumference, AMH, TT, FT, LH, and LH/FSH decreased significantly (P<0.05), whereas SHBG increased significantly (P<0.05). There was no significant difference in AMH, LH/FSH, and TT between PCOS and control groups after treatment (P>0.05). Conclusion After 3 months of comprehensive intervention, the androgen level of PCOS patients was significantly decreased, especially the total testosterone level reached the level of healthy women.

Key words: polycystic ovary syndrome, total testosterone, free testosterone, sex hormone binding globulin

CLC Number:

R711

Wang Binhong, Ruan Xiangyan, Ju Rui, Dou Zhuli, Qin Shuang, Zhang Luping, Xu Xin, Yang Yu, Alfred O. Mueck. Effect of comprehensive intervention on androgen level in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2020, 41(4): 520-524.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.04.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I4/520

References 19

[1]	宋颖,李蓉. 多囊卵巢综合征中国诊疗指南解读[J].实用妇产科杂志,2018,34(10):737-741.
[2]	Zeng X,Xie Y J, Liu Y T, et al. Polycystic ovarian syndrome:correlation between hyperandrogenism, insulin resistance and obesity[J]. Clin Chim Acta,2020,3(502):214-221.
[3]	Sanchez-Garrido M A,Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome:pathogenic role of androgen excess and potential therapeutic strategies[J]. Mol Metab,2020,5(35):100937.
[4]	Lizneva D,Suturina L,Walker W,et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome[J]. Elsevier Inc,2016, 106(1):6-15.
[5]	March W A,Moore V M,Willson K J,et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria[J]. Hum Reprod,2010,25(2):544-551.
[6]	张美微,侯丽辉,李妍,等.多囊卵巢综合征相关合并症的研究进展[J].现代中西医结合杂志,2020,29(2):214-219.
[7]	Pan J X,Liu Y,Ke Z H,et al. Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess[J]. Gynecol Endocrinol, 2015,1(4):332-336.
[8]	Li Y,Ruan X,Wang H,et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J]. Fertil Steril, 2018,109(4):720-727.
[9]	中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018,53(1):2-6.
[10]	Calzada M,López N,Noguera J A, et al. AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome[J]. J Obstet Gynaecol, 2019,39(8):1130-1136.
[11]	Li G,Huang W,Zhang L, et al. A prospective cohort study of early-pregnancy risk factors for gestational diabetes in polycystic ovarian syndrome[J]. Diabetes Metab Res Rev, 2018,34(5):e3003.
[12]	Tian X,Ruan X,Mueck A O,et al. Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China[J]. Gynecol Endocrinol, 2014, 30(11):836-839.
[13]	Zhao Y, Ruan X, Mueck A O. Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes[J]. Gynecol Endocrinol, 2016,32(2):151-156.
[14]	郑荣荣,袁为标,周蓉,等.口服避孕药增加静脉血栓发病率的Meta分析[J].现代妇产科进展,2019,28(10):774-780.
[15]	战思恩,于朝.性激素结合球蛋白与多囊卵巢综合征患者肥胖、血糖、胰岛素及性激素的相关性研究[J].中国妇幼保健,2019,34(10):2229-2231.
[16]	罗卓野,张杰,郝桂敏.多囊卵巢综合征伴肥胖者助孕前处理[J].中国实用妇科与产科杂志,2019,35(3):287-291.
[17]	Cesta C E,MÅnsson M,Palm C,et al. Polycysti covary syndrome and psychiatric disorders:Comorbidity and heritability in a nation wide Swedish cohort[J]. Psychoneuroendocrinology,2016, 73(11):196-203.
[18]	杨荔凡,张艳.屈螺酮炔雌醇复合片对多囊卵巢综合征患者的有效性探讨[J].中外女性健康研究,2019,12(23):85,101.
[19]	闵敏,阮祥燕,赵越,等. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J].首都医科大学学报,2019,40(4):572-577.